PT - JOURNAL ARTICLE AU - Nico Scheer AU - Yury Kapelyukh AU - Jillian McEwan AU - Vincent Beuger AU - Lesley A Stanley AU - Anja Rode AU - Charles Roland Wolf TI - Modeling Human Cytochrome P450 2D6 Metabolism and Drug-drug Interaction by a Novel Panel of Knockout and Humanized Mouse Lines AID - 10.1124/mol.111.075192 DP - 2011 Oct 11 TA - Molecular Pharmacology PG - mol.111.075192 4099 - http://molpharm.aspetjournals.org/content/early/2011/10/11/mol.111.075192.short 4100 - http://molpharm.aspetjournals.org/content/early/2011/10/11/mol.111.075192.full AB - The highly polymorphic human Cytochrome P450 CYP2D6 enzyme is involved in the metabolism of up to 25% of all marketed drugs and accounts for significant individual differences in response to CYP2D6 substrates. Due to the differences in the multiplicity and substrate specificity of CYP2D members between species, it is difficult to predict pathways of human CYP2D6-dependent drug metabolism on the basis of animal studies. In order to create animal models which reflect the human situation more closely and which allow an in vivo assessment of the consequences of differential CYP2D6 drug metabolism, we have developed a novel straightforward approach to delete the entire murine Cyp2d gene cluster and replace it with allelic variants of human CYP2D6. By using this approach, we have generated mouse lines expressing the two frequent human protein isoforms CYP2D6.1 and CYP2D6.2 and an as yet undescribed variant of this enzyme, as well as a Cyp2d cluster knockout mouse. We demonstrate that the various transgenic mouse lines cover a wide spectrum of different human CYP2D6 metabolizer phenotypes. The novel humanization strategy described here provides a robust approach for the expression of different CYP2D6 allelic variants in transgenic mice and thus can help to evaluate potential CYP2D6-dependent inter-individual differences in drug response in the context of personalized medicine.